Human Experimentation and Research
-10%
portes grátis
Human Experimentation and Research
Tomossy, George F.; Weisstub, David N.
Taylor & Francis Ltd
01/2019
652
Mole
Inglês
9781138709584
15 a 20 dias
1210
Descrição não disponível.
Contents: Series preface; Introduction: human research ethics. Part I: The Historical and Philosophical Foundations: Philosophical reflections on experimenting with human subjects, Hans Jonas (1969); Experimenting on human subjects: philosophical perspectives, Ruth Macklin and Susan Sherwin (2004); Principlism and the ethical appraisal of clinical trials, Eric M. Meslin, Heather J. Sutherland, James V. Lavery and James E. Till; The Nuremberg code in light of previous principles and practices in human experimentation, David J. Rothman; Nuremberg's legacy: some ethical reflections, James F. Childress; The controversy over retrospective moral judgment, Allen Buchanan; Looking back and judging our predecessors, Tom L. Beauchamp; When evil intrudes, Arthur L. Caplan; Shading the truth in seeking informed consent for research purposes, Sissela Bok; Trust: the fragile foundation of contemporary biomedical research, Nancy E. Kass, Jeremy Sugarman, Ruth Faden and Monica Schoch-Spana; Questing for grails: duplicity, betrayal and self-deception in postmodern medical research, George J. Annas; Roles and fictions in clinical and research ethics, David N. Weisstub. Part II: Protecting Human Subjects: Human experimentation and human rights, Jay Katz; The social control of human biomedical research: an overview and review of the literature, Paul R. Benson; Goodbye to all that: the end of moderate protectionism in human subjects research, Jonathan D. Moreno; Is national, independent oversight needed for the protection of human subjects?, Alexander Morgan Capron; National, independent oversight: reinforcing the safety net for human subjects research, Anna C. Mastroianni; Regulating research for the decisionally impaired: implications for mental health professionals, Marshall B. Kapp; Are research ethics bad for our mental health?, Robert Michels; The reform of adult guardianship laws: the case of non-therapeutic experimentation; George F. Tomossy and David N. Weisstub. Part III: Risk and Responsibility: The ethical analysis of risk, Charles Weijer; Defining and describing benefit appropriately in clinical trials, Nancy M.P. King; What research with stored samples teaches us about research with human subjects, David Wendler; Uncertainty in clinical research; Robert J. Levine; Equipoise and the ethics of clinical research, Benjamin Freedman; Equipoise, knowledge and ethics in clinical research and practice, Richard Ashcroft; Ethical considerations concerning treatment allocation in drug development trials, S. Senn; When are placebo-controlled trials no longer appropriate?, Baruch A. Brody. Part IV: Globalization and Corporation - Trust and Participation: International research: ethical imperialism or ethical pluralism?, Ruth Macklin; Is academic medicine for sale?, Marcia Angell; Ethical issues in research relationships between universities and industry, James T. Rule and Adil E. Shamoo; Uneasy alliance - clinical investigators and the pharmaceutical industry, Thomas Bodenheimer; Ethics review for sale? Conflict of interest and commercial research review boards, Trudo Lemmens and Benjamin Freedman; Dealing with conflicts of interest in biomedical research: IRB oversight as the next best solution to the abolitionist approach, Jesse A. Goldner; Restoring and preserving trust in biomedical research, Mark Yarborough and Richard R. Sharp; Privatized biomedical research, public fears, and the hazards of government regulation: lessons from stem cell research, David B. Resnik; Name index.
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
IRB;Experiments;Institutional Review Board;Research;Informed Consent;Human;National Bio-ethics Advisory Commission;Hans Jonas;Violating;Ruth Macklin;Clinical Equipoise;Susan Sherwin;Human Research Subjects;Eric M. Meslin;IRB Member;Heather J. Sutherland;Nuremberg Code;James V. Lavery;Human Subject Protection;James E. Till;Non-therapeutic Research;David Rothman;National Bioethics Advisory Commission;James Childress*;Clinical Practice;Allen Buchanan;Human Radiation Experiments;Tom L. Beauchamp;Prospective Subject;Arthur L. Caplan;Review Board;Sissela Bok;NBAC Report;Nancy E. Kass;Therapeutic Misconception;Jeremy Sugarman;Biomedical Research Involving Human Subjects;Ruth Faden;Biomedical Research;Monica Schoch-Spana;Research Ethics Review;George J. Annas;CIOMS;David N. Weisstub;PHS;Jay Katz;Therapeutic Research;Paul R. Benson;APA;Jonathan D. Moreno;Alexander Morgan Capron;Anna C. Mastroianni;Marshall B. Kapp;Robert Michels;Charles Weijer;Nancy M. P. King;David Wendler;Robert J. Levine;Benjamin Freedman;Richard Ashcroft;S. Senn;Baruch A. Brody;Ruth Macklin*;Marcia Angell;James T. Rule;Adil E. Shamoo;Thomas Bodenheimer;Trudo Lemmens;Jesse A. Goldner;Mark Yarborough;Richard R. Sharp;David B. Resnik;ethical implications;research ethics;ongoing regulatory dilemmas
Contents: Series preface; Introduction: human research ethics. Part I: The Historical and Philosophical Foundations: Philosophical reflections on experimenting with human subjects, Hans Jonas (1969); Experimenting on human subjects: philosophical perspectives, Ruth Macklin and Susan Sherwin (2004); Principlism and the ethical appraisal of clinical trials, Eric M. Meslin, Heather J. Sutherland, James V. Lavery and James E. Till; The Nuremberg code in light of previous principles and practices in human experimentation, David J. Rothman; Nuremberg's legacy: some ethical reflections, James F. Childress; The controversy over retrospective moral judgment, Allen Buchanan; Looking back and judging our predecessors, Tom L. Beauchamp; When evil intrudes, Arthur L. Caplan; Shading the truth in seeking informed consent for research purposes, Sissela Bok; Trust: the fragile foundation of contemporary biomedical research, Nancy E. Kass, Jeremy Sugarman, Ruth Faden and Monica Schoch-Spana; Questing for grails: duplicity, betrayal and self-deception in postmodern medical research, George J. Annas; Roles and fictions in clinical and research ethics, David N. Weisstub. Part II: Protecting Human Subjects: Human experimentation and human rights, Jay Katz; The social control of human biomedical research: an overview and review of the literature, Paul R. Benson; Goodbye to all that: the end of moderate protectionism in human subjects research, Jonathan D. Moreno; Is national, independent oversight needed for the protection of human subjects?, Alexander Morgan Capron; National, independent oversight: reinforcing the safety net for human subjects research, Anna C. Mastroianni; Regulating research for the decisionally impaired: implications for mental health professionals, Marshall B. Kapp; Are research ethics bad for our mental health?, Robert Michels; The reform of adult guardianship laws: the case of non-therapeutic experimentation; George F. Tomossy and David N. Weisstub. Part III: Risk and Responsibility: The ethical analysis of risk, Charles Weijer; Defining and describing benefit appropriately in clinical trials, Nancy M.P. King; What research with stored samples teaches us about research with human subjects, David Wendler; Uncertainty in clinical research; Robert J. Levine; Equipoise and the ethics of clinical research, Benjamin Freedman; Equipoise, knowledge and ethics in clinical research and practice, Richard Ashcroft; Ethical considerations concerning treatment allocation in drug development trials, S. Senn; When are placebo-controlled trials no longer appropriate?, Baruch A. Brody. Part IV: Globalization and Corporation - Trust and Participation: International research: ethical imperialism or ethical pluralism?, Ruth Macklin; Is academic medicine for sale?, Marcia Angell; Ethical issues in research relationships between universities and industry, James T. Rule and Adil E. Shamoo; Uneasy alliance - clinical investigators and the pharmaceutical industry, Thomas Bodenheimer; Ethics review for sale? Conflict of interest and commercial research review boards, Trudo Lemmens and Benjamin Freedman; Dealing with conflicts of interest in biomedical research: IRB oversight as the next best solution to the abolitionist approach, Jesse A. Goldner; Restoring and preserving trust in biomedical research, Mark Yarborough and Richard R. Sharp; Privatized biomedical research, public fears, and the hazards of government regulation: lessons from stem cell research, David B. Resnik; Name index.
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
IRB;Experiments;Institutional Review Board;Research;Informed Consent;Human;National Bio-ethics Advisory Commission;Hans Jonas;Violating;Ruth Macklin;Clinical Equipoise;Susan Sherwin;Human Research Subjects;Eric M. Meslin;IRB Member;Heather J. Sutherland;Nuremberg Code;James V. Lavery;Human Subject Protection;James E. Till;Non-therapeutic Research;David Rothman;National Bioethics Advisory Commission;James Childress*;Clinical Practice;Allen Buchanan;Human Radiation Experiments;Tom L. Beauchamp;Prospective Subject;Arthur L. Caplan;Review Board;Sissela Bok;NBAC Report;Nancy E. Kass;Therapeutic Misconception;Jeremy Sugarman;Biomedical Research Involving Human Subjects;Ruth Faden;Biomedical Research;Monica Schoch-Spana;Research Ethics Review;George J. Annas;CIOMS;David N. Weisstub;PHS;Jay Katz;Therapeutic Research;Paul R. Benson;APA;Jonathan D. Moreno;Alexander Morgan Capron;Anna C. Mastroianni;Marshall B. Kapp;Robert Michels;Charles Weijer;Nancy M. P. King;David Wendler;Robert J. Levine;Benjamin Freedman;Richard Ashcroft;S. Senn;Baruch A. Brody;Ruth Macklin*;Marcia Angell;James T. Rule;Adil E. Shamoo;Thomas Bodenheimer;Trudo Lemmens;Jesse A. Goldner;Mark Yarborough;Richard R. Sharp;David B. Resnik;ethical implications;research ethics;ongoing regulatory dilemmas
